Frederick National Laboratory for Cancer Research
8560 Progress Drive
About Frederick National Laboratory for Cancer Research
A rewarding career with global impact
Whether you’re an expert in your field or just starting out, we have a career opportunity for you. We’re always looking for people to join us in fulfilling the mission of the Frederick National Laboratory: discovery, innovation, and success in the biomedical sciences.
Our team of 2,400+ scientists, technicians, administrators, and support staff work at the forefront of basic, translational, and preclinical science, with a focus on cancer, AIDS, and other infectious diseases.
We collaborate with colleagues across the National Cancer Institute, National Institutes of Allergy and Infectious Diseases, and others throughout the National Institutes of Health. We also engage with extramural investigators in academia, government and industry.
Your path to joining our team begins with the desire to work for the only national laboratory dedicated to biomedical research. Our employees share a common desire to help make a difference in cancer research and public health concerns. As you search for a career that fits your education, skills, and abilities, explore the core values that guide us and emphasize work-life balance.
Discover why joining the Frederick National Laboratory team could be the most important career step you take
Our core values of accountability, compassion, collaboration, dedication, integrity, and versatility serve as a guidepost for how we do our work every day in serving the public's interest.
45 articles with Frederick National Laboratory for Cancer Research
1/11/2022According to recent BioSpace research, 78% of employers indicated that the number of open roles will be in increasing for 2022. More positions open, the better the odds of finding a new job.
Nanotechnology Characterization Laboratory Supports Long-Term Study Evaluating Toxicity from Nanoparticles
The Frederick National Laboratory’s Nanotechnology Characterization Laboratory recently supported a first-of-its-kind study examining whether nanoparticles used for drug delivery, vaccines, and biomedical imaging were toxic over an extended period of time.
Results from genomic testing of a cancer patient’s biopsy tissue can help guide treatment decisions, depending on the types of gene mutations found. But as it spreads or stops responding to treatment, the cancer changes and develops new mutations. Insights gained from the biopsy of the primary tumor may no longer be relevant in determining next steps.
A “Swiss army knife” protein that is active against several viruses may also offer some protection against Nipah virus, a lethal pathogen with no cure or vaccine.
FHI Clinical Inc. Providing Clinical Operations Services for ACTT-1 Trial of Remdesivir for Treatment of COVID-19
FHI Clinical Inc. contracted by Frederick National Laboratory for Cancer Research, currently operated by Leidos Biomedical Research, Inc., to provide operational support for NIAID-funded study DURHAM, N.C.--( BUSINESS WIRE )-- FHI Clinical Inc. announced that it has a subcontract with the Frederick National Laboratory for Cancer Research, currently operated by Leidos Biomedical Research, Inc., to provide clinical operations services for the Adaptiv
Studies Show HLA-B Gene Match with Recipient and Donor May Lead to More Successful Bone Marrow Transplant
For patients with blood cancer such as leukemia, a bone marrow transplant can extend life or even potentially cure the disease. The ideal bone marrow donor is a close relative, such as a brother or sister. If none is available, doctors look for an unrelated donor whose stem cells best match those of the recipient.
A unique library of small-molecule fragments designed and developed by the National Cancer Institute’s RAS Initiative at the Frederick National Laboratory is now furthering the search for a COVID-19 treatment.
The Frederick National Laboratory for Cancer Research has initiated a new technical service offering, to support tuberculosis vaccine research efforts in nonhuman primate (NHP) model studies.
Frederick National Laboratory scientists optimize SARS-CoV-2 protein production to meet growing need for serology testing
Scientists at the Frederick National Laboratory for Cancer Research (FNL) successfully increased the yield production of a challenging protein used in antibody tests for SARS-CoV-2, the virus behind COVID-19, publishing their findings earlier this month in Protein Expression and Purification.
Scientific partnership including Frederick National Laboratory develops highly specific test to detect antibodies to COVID-19
Scientists at the Frederick National Laboratory for Cancer Research and investigators across the National Institutes of Health (NIH) have developed a highly specific serology test to determine whether a person has antibodies to SARS-CoV-2, a vital tool to understanding the spread of infection from the virus that causes COVID-19.
A type of the human papillomavirus (HPV) that is relatively uncommon among all women is more prevalent among women of African ancestry in the United States according to a National Cancer Institute study published in the International Journal of Cancer and co-authored by scientists at the Frederick National Laboratory for Cancer Research.
Analyzing tumors of cancer patients with robust response to treatment may offer clues on how others can benefit and improve tailored treatment
Patients who have a better-than-average response to cancer treatment can help further research that might benefit all cancer patients. Analysis of their tumor tissues can provide clues about the genetic keys that make their tumor more responsive to treatment.
Malian Prime Minister visits CMRPD-supported University Clinical Research Center pivoting to COVID-19 research
As word of the SARS-CoV-2 outbreak spread around the world, countries began looking inward to prepare. In Mali, Prime Minister Dr. Boubou Cisse visited University Clinical Research Center (UCRC) laboratories at the University of Sciences, Techniques, and Technologies of Bamako (USTTB) in March to see how its facilities could help.
New England Journal of Medicine paper shows remdesivir speeds recovery for Hospitalized COVID-19 patients
The antiviral treatment remdesivir accelerated recovery time among hospitalized participants with advanced COVID-19 compared to participants who received placebo containing inactive ingredients, according to results of a clinical trial published May 22 in the New England Journal of Medicine.
Collaboration with the London School of Hygiene & Tropical Medicine investigates a single-dose HPV vaccine in Tanzania
Is a single dose of a human papillomavirus (HPV) vaccine sufficient to induce an immune response capable of preventing HPV infection and cervical cancer? That is an area of focus of the Frederick National Laboratory’s HPV Serology Laboratory, this time with a new collaboration with the London School of Hygiene & Tropical Medicine School to investigate immune responses to a single dose of the HPV vaccine in girls in Tanzania.
FNL supports website development for official COVID-19 treatment guidelines
The Pamoja Tulinde Maisha (PALM, Kiswahili for “together save lives”) trial, a large Ebola research effort supported by the Frederick National Laboratory, has received the David Sackett Trial of the Year Award for 2019.
Study on “rapid autopsy” tumor tissue as a valuable research tool is among abstracts presented at 2020 ASCO Virtual Scientific Program
Tissue obtained from tumors during an autopsy conducted shortly after a cancer patient’s death provides unique insights into how the tumors evolved, spread and resisted treatment. The Frederick National Laboratory’s Molecular Characterization Laboratory reports on results of a study on preclinical models established from “rapid autopsy” tumors during the 2020 American Society for Clinical Oncology Virtual Scientific Program, May 29-31.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 22, 2020.
In its urgent efforts to confront the novel coronavirus, the U.S. Food and Drug Administration (FDA) has tapped the Frederick National Laboratory for Cancer Research (FNL) to scientifically inform its decision-making on potential approval of blood tests for the presence of antibodies to SARS-CoV-2.